The current most commonly used test for bowel cancer screening is the Feacal Occult Blood Test (FOBT). As it simply recognises blood in the stool the test is non-specific for colorectal cancer. Hence the interpretation of the result can be very difficult and inexact. In addition, only bleeding colorectal tumors – if at all – are recognised. The largest study conducted so far on this subject is the American Veterans Association study in which a total of 2885 participants underwent total colonoscopy. The results are that only 23,9% of those participants with advanced neoplasia had a positive faecal occult blood test.
The Tumor M2-PK™ Stool Test is a totally new approach, which is much more sensitive than previous laboratory bowel cancer screening tests. Previously, only non-specific tests for blood in the stool could be used to give an indication of an existing bowel cancer or its precursors. With the new ELISA method for Tumor M2-PK in the stool it′s now possible to detect bleeding or non-bleeding bowel cancers, as well as polyps, with high sensitivity and specificity. The test is more accurate because it is not dependent on occult blood.
The main advantages of the Tumor M2-PK™ Stool Test are:
* High sensitivity
* High specificity
* Not dependent on occult blood
* Detects bleeding or non-bleeding bowel polyps, especially >1cm
* Detects bleeding or non-bleeding bowel tumours
* Not affected by particular foods
* No special diet required
* No false results from haemorrhoids or other sources of blood in the bowel
* A single pea-sized sample is sufficient
The Tumor M2-PK™ Stool Test detects about 85% of all tumors with single testing . This is much better than only 30% at most with the faecal occult blood test. Even polyps are detected:
If you would like to know more about Tumor M2-PK™ and are interested to market Tumor M2-PK™ in Malaysia and Indonesia, please contact us at email@example.com